Bivalent Subtype C gp120
PreclinicalBiologic
Bivalent Subtype C gp120 is one of 18 biologic programs targeting HIV Infections. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in HIV Infections
#DrugCompanyPhaseTrials
1Cabenuva
GSKPhase 3
Tivicay
GSKPhase 3
Biktarvy
GileadPhase 3
Sunlenca
GileadPhase 3
CAB LA
GSKPhase 3
Fostemsavir
GSKPhase 3
Rhuph20
Bristol-Myers SquibbPhase 2
Teropavimab
GileadPhase 3
Zinlirvimab
GileadPhase 3
APRETUDE
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Immunogenicity2 trials
Immune Response1 trial
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02404311·252 enrolled
Safety and Efficacy1 trial
Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2/3·NCT02968849·5,404 enrolled
HIV Infections1 trial
A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT03284710·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bivalent Subtype C gp120. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details